Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.
Revenue (Most Recent Fiscal Year) | $66.71M |
Net Income (Most Recent Fiscal Year) | $-8.19M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.38 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -12.28% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | 3.73 |
Quick Ratio (Most Recent Fiscal Quarter) | 3.73 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.60 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.69 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | $-0.10 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 80.86M |
Free Float | 55.07M |
Market Capitalization | $190.02M |
Average Volume (Last 20 Days) | 0.01M |
Beta (Past 60 Months) | 0.30 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 31.89% |
Percentage Held By Institutions (Latest 13F Reports) | 0.16% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |